Vaccine that targets several amyloid (Aβ) and tau pieces for Alzheimer's
Official title: Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes
Funded at Pop Biotechnologies, INC · NIH-11256011 · Data updated 2026-11-12
This project is making a vaccine that trains the immune system to target both amyloid and tau proteins to help people at risk for or living with Alzheimer's disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 15, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $833,334 |
| NIH project number | 2R42AG082620-03 |
| Project ID | NIH-11256011 on NIH RePORTER |
Who could benefit from this research
✓Could help
People at risk for Alzheimer's disease or in the early stages of Alzheimer's would be the most likely candidates for future vaccine trials.
✕Less likely to help
People with advanced Alzheimer's, significant immune disorders, or known allergies to vaccine components may not be suitable or receive benefit.
What this research studies
Researchers are creating a 'mosaic' vaccine that displays multiple pieces of the Aβ and tau proteins on tiny lipid particles called SNAP liposomes to trigger a broader immune response. They will scale up manufacturing, develop quality and analytical tests, and run lab and animal studies to check immune responses, safety, and effects on Alzheimer-like brain changes. The work uses established Alzheimer's animal models and preclinical safety testing as steps toward an Investigational New Drug (IND) application. If those steps go well, the vaccine could move into early human safety trials.
Why it matters
Potential benefit: If successful, this vaccine could lower both amyloid and tau pathology and potentially slow or prevent cognitive decline in people with or at risk for early Alzheimer's disease.
How similar studies have gone: Some monoclonal antibodies that clear amyloid have modestly slowed decline in early Alzheimer's, but combined vaccines targeting both amyloid and tau are largely novel and unproven in humans.
Where this research is happening
-
Pop Biotechnologies, INC
Buffalo, United States Active
Researchers
- Principal investigator: Huang, Wei-Chiao — Pop Biotechnologies, INC
- Study coordinator: Huang, Wei-Chiao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.